Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis

• Published in: In vivo (Athens) Vol. 37; no. 3; pp. 1037 - 1046
• Main Authors: CHIU, HONG-YI, TSAI, SHIH-CHANG, TSAI, FUU-JEN, LO, YU-HSIANG, CHENG, CHING-CHANG, LIU, TING-YUAN, JHAN, SYUN-RONG, YANG, JAI-SING, CHIU, YU-JEN
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.05.2023
• Subjects: Alanine Transaminase; Animals; Choline - metabolism; Choline - pharmacology; Choline - therapeutic use; Diabetes; Diet; Disease Models, Animal; Enzymes; Fatty liver; FDA approval; Glucagon; Insulin resistance; Laboratory animals; Liraglutide - metabolism; Liraglutide - pharmacology; Liraglutide - therapeutic use; Liver - pathology; Liver cirrhosis; Metabolism; Metformin - pharmacology; Methionine - metabolism; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - metabolism; Obesity; Variance analysis; Weight control; United States > US; MCD diet; metformin; liver injury; C57BL/6JNarl mouse model; Liraglutide; non-alcoholic steatohepatitis
• ISSN: 0258-851X; 1791-7549; 1791-7549
• DOI: 10.21873/invivo.13178

Non-alcoholic fatty liver disease is a major cause of liver-related morbidity and mortality. Metformin is a widely used medication and may have additional benefits beyond glycemic control. Liraglutide, a novel treatment for diabetes and obesity, also has beneficial effects on non-alcoholic steatohep...